Scancell Holdings PLC (GB:SCLP)
LSE:SCLP
SCLP Stock Chart & Stats
9.75 p
0.40 p(4.06%)
At close: 4:00 PM EST
9.75 p
0.40 p(4.06%)
Day’s Range― - ―
52-Week Range7.80 p - 14.00 p
Previous CloseN/A
Volume797.06K
Average Volume (3M)1.20M
Market Cap
£116.75M
Enterprise Value124.36M
Total Cash (Recent Filing)£8.57M
Total Debt (Recent Filing)£16.18M
Price to Earnings (P/E)―
Beta0.21
Next Earnings
Oct 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,037,781,400
10 Day Avg. Volume991,653
30 Day Avg. Volume1,200,950
Financial Highlights & Ratios
PEG Ratio-0.10
Price to Book (P/B)-27.20
Price to Sales (P/S)22.14
P/FCF Ratio-17.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.01
Revenue Forecast (FY)£833.33K
Bulls Say, Bears Say
Bulls Say
Regulatory/Registrational ProgressIND clearance materially reduces regulatory execution risk by validating the dose, delivery, endpoints and manufacturing package, enabling a defined registrational pathway and accelerated approval options. This creates a durable development trajectory and makes partnering and financing discussions more concrete over the next 2–6 months.
Robust Phase II Efficacy & BiomarkerA strong Phase II PFS signal plus an identified biomarker and an adaptive Phase III design materially lowers clinical development risk. Biomarker enrichment and adaptive statistics improve the probability of a successful registrational outcome and enhance the program's attractiveness to partners long-term.
Partnered Upside & Commercial EnablersA material licensing framework with Genmab and clear milestone economics provides credible non-dilutive value pathways. Coupled with scalable manufacturing and commercial delivery partnerships cited by management, this strengthens long-term commercialization viability and partner-driven funding options.
Bears Say
Negative Shareholder EquityPersistent negative equity signals structural balance-sheet weakness, reducing financial flexibility and making leverage metrics less informative. This limits the company's ability to absorb shocks, raises counterparty concerns, and increases the likelihood that future development will require dilution or onerous financing terms.
Ongoing Cash Burn / Limited Cash GenerationOperating losses translate into sustained negative cash flow despite improvement in 2025. Continued cash burn means management must secure financing or milestone receipts to sustain Phase III and pipeline programs, creating ongoing funding pressure that structurally affects strategic choices and partner negotiations.
Long Timing To Registrational ReadoutA multi-year blinded Phase III extends the period of clinical uncertainty and delays definitive value realization. The long timeline increases cumulative funding needs, prolongs exposure to execution risk and means investors and partners face a protracted wait for confirmatory data and potential commercialization.
Scancell Holdings News
SCLP FAQ
What was Scancell Holdings PLC’s price range in the past 12 months?
Scancell Holdings PLC lowest share price was 7.80 p and its highest was 14.00 p in the past 12 months.
What is Scancell Holdings PLC’s market cap?
Scancell Holdings PLC’s market cap is £116.75M.
When is Scancell Holdings PLC’s upcoming earnings report date?
Scancell Holdings PLC’s upcoming earnings report date is Oct 23, 2026 which is in 202 days.
How were Scancell Holdings PLC’s earnings last quarter?
Scancell Holdings PLC released its earnings results on Jan 29, 2026. The company reported -0.006 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.006 p.
Is Scancell Holdings PLC overvalued?
According to Wall Street analysts Scancell Holdings PLC’s price is currently Overvalued.
Does Scancell Holdings PLC pay dividends?
Scancell Holdings PLC does not currently pay dividends.
What is Scancell Holdings PLC’s EPS estimate?
Scancell Holdings PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Scancell Holdings PLC have?
Scancell Holdings PLC has 1,037,781,400 shares outstanding.
What happened to Scancell Holdings PLC’s price movement after its last earnings report?
Scancell Holdings PLC reported an EPS of -0.006 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.804%.
Which hedge fund is a major shareholder of Scancell Holdings PLC?
Currently, no hedge funds are holding shares in GB:SCLP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Scancell Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-29.25%
12-Months-Change
Fundamentals
Return on Equity
90.29%
Trailing 12-Months
Asset Growth
-7.40%
Trailing 12-Months
Company Description
Scancell Holdings PLC
Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel vaccines and antibody medicines to treat unmet needs in cancer and infectious diseases. The company's product candidates include SCIB1, which is in phase II clinical trial for the treatment of metastatic melanoma; SCIB2 for the treatment of non-small cell lung cancer; and Modi-1 that is in phase I/II clinical trials for the treatment of head and neck, triple negative breast, ovarian, and renal cancers. It also develops Modi-2, which targets homocitrullinated cancer antigens. In addition, the company develops SCOV1 and SCOV2 COVIDITY, a prophylactic DNA vaccine against the SARS-CoV-2 virus. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.
Technical Analysis
Sareum Holdings
―
4basebio UK Societas
―
Poolbeg Pharma Ltd.
―
Arecor Therapeutics PLC
―
Ondine Biomedical, Inc.
―
Options Prices
Currently, No data available
---